Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Olympus: New Reaction/Analysis System FD10
October 7, 2002
- Results of Reexamination for 22 Active Ingredients Announced
October 7, 2002
- Baxter Transfers Cardiovascular Products to Edwards Lifesciences in Japan
October 7, 2002
- DIA Conference on Pharmaceutical Evolution in Asia
October 7, 2002
- New Chugai Inaugurated
October 7, 2002
- Relief of Lower Back Pain Increases Patients' Satisfaction with Osteoporosis Drugs
October 7, 2002
- WORLD NEWS IN BRIEF
October 7, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
October 7, 2002
- ENGLISH BOOK
October 7, 2002
- Maurer's Healthcare Insight (34)
October 7, 2002
- BULLETIN
October 7, 2002
- JP Should Be in Greater Harmony with Pharmacopoeias from Other Countries: Seminar
October 7, 2002
- Pursuing Fusion & Application of Intellectual Property: Mr Nakamura of Nippon Kayaku
October 7, 2002
- Fujisawa to Enhance Profitability by Splitting Off Plants, Chemical Division
October 7, 2002
- REGULATORY NEWS IN BRIEF
October 7, 2002
- Nippon Chemiphar Ties Up with Ranbaxy of India
October 7, 2002
- JPMA to Gear Up Efforts to Protect IP
October 7, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 7, 2002
- Dr Sakaguchi Shows Direction for Medical Fee System Reform: Economist Conferences
October 7, 2002
- Sales Up, But Gross Profit Margin Down 4.14%: FJPWA Survey
October 7, 2002
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…